Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The 28% nausea rate versus 44% is a significant difference that affects daily quality of life during treatment
The 2-year STEP 5 study discussed here aimed to assess the sustained impact of weekly subcutaneous semaglutide 2.4 mg, in conjunction with behavioral interventions, on body weight and cardiometabolic risks among non-diabetic adults grappling with obesity (BMI 30 kg m2) or overweight (BMI 27 kg m2 with at least one related comorbidity)
The trial that kicked off the modern obesity-medication era
Blood tests: To measure hormone levels (testosterone, growth hormone) and peptide activity
Nagasawa Y et al
As weight loss occurs and metabolic parameters improve , blood pressure may decrease, potentially requiring adjustment of existing blood pressure medications
